Tirzepatide is a synthetic research peptide that has attracted significant scientific attention due to its dual-agonist mechanism. Unlike traditional GLP-1 receptor agonists studied in metabolic research, Tirzepatide simultaneously activates both GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) receptors — a characteristic that makes it a valuable compound for investigating multi-pathway hormonal signalling.
GLP-1 and GIP: The Two Incretin Pathways
Incretin hormones are released from the gut in response to food intake and play a role in regulating insulin secretion and glucose metabolism. The two primary incretin pathways are:
- GLP-1 — stimulates insulin release, suppresses glucagon, and slows gastric emptying
- GIP — enhances insulin secretion and has been studied for its role in fat metabolism
Most earlier peptide research compounds targeted only GLP-1. Tirzepatide’s dual-receptor activity makes it useful for studying the combined or comparative effects of both pathways.
Research Applications
Tirzepatide is studied in laboratory settings for:
- Investigating dual incretin receptor crosstalk
- Metabolic signalling research
- Comparative studies between single and dual receptor agonism
- Hormonal regulation research models
Available Formats at Alluvi Peptides
Alluvi Peptides supplies Tirzepatide in two formats for laboratory use:
Both are supplied with batch-specific COA, HPLC verification, and discreet UK dispatch.